Medical device makers and pharmaceutical companies expanding across borders often discover the hard way that treating each market as an isolated translation project creates more problems than it solves. Instructions for Use that read one way in German and another in Japanese, labeling that drifts from the approved English source, or clinical trial materials that use conflicting terms for the same adverse event—these are not minor inconsistencies. They erode brand trust, invite regulatory scrutiny, and drive up costs year after year.
The root issue is rarely a lack of translators. It is the absence of a deliberate plan for managing the organization’s medical language assets: the translation memories that store previously approved segments and the termbases that lock in preferred terminology across every document, interface, and market.
Where Fragmentation Shows Up in Practice
Consider the typical path. A company launches a Class III cardiac device in the United States, then begins preparing for European markets under the MDR. Separate language vendors handle the French, Spanish, Italian, and German versions of the IFU. Each team works from slightly different source files or legacy materials. Preferred terms for device components, contraindications, or procedural steps are decided locally. By the time the full set reaches the notified body, reviewers flag mismatches that force rework.
A documented case involving a U.S. manufacturer of an implantable cardiac device illustrates the scale of the problem and the payoff of fixing it early. Legacy content from multiple product families and prior vendors had produced fragmented terminology. By first reconciling that material into a single controlled vocabulary—before scaling to 24 languages—the localization program shortened the client’s QA cycle by 30 percent and completed notified-body review with zero translation-related revisions. The device stayed on its regulatory schedule.
Similar patterns appear across the industry. FDA warning letters repeatedly cite labeling and promotional materials that fail to match approved claims or use inconsistent wording. In one frequently referenced example, an IVD antigen test faced recall because performance claims on labeling did not align with clinical data. Regulators treat websites, patient guides, and packaging as extensions of the product file; divergence across languages is treated as a compliance risk, not a linguistic preference.
The financial side is equally concrete. When translation memory and termbase assets remain siloed with individual vendors, exact and fuzzy matches are never fully leveraged. One global medical technologies company working with a specialized provider translated more than 6.3 million words into 34-plus languages while generating over $1 million in technology-driven savings and doubling the volume of up-to-date documentation available for global use. The difference came from centralized linguistic assets rather than repeated full-price translation of recurring content.
What a Systematic Language Asset Strategy Actually Looks Like
A workable enterprise approach begins with extraction, not invention. Source materials already in the company’s possession—510(k) or PMA submissions, existing IFUs, CER/SSCP documents, clinical protocols, and prior approved translations—become the raw material for a master termbase. Each entry carries definition, context, preferred translation, forbidden variants, and regulatory notes. MedDRA, WHODrug, GMDN/EMDN nomenclature, and ICH/EMA QRD templates provide external anchors so that internal terms stay aligned with the systems regulators and safety databases already use.
Translation memory is built in parallel. Every approved segment is stored with metadata that records version, product family, and market. When a new IFU update or labeling change arrives, the system surfaces 100 percent matches and high-fuzzy matches automatically. Translators and reviewers spend time only on genuine new content. Over successive releases the asset library compounds in value; the more markets a company enters, the lower the marginal cost of accurate localization.
Governance prevents drift. A single source of truth—accessible to regulatory, marketing, clinical, and localization teams—enforces the approved terms. Changes flow through a controlled process so that an update in one language does not silently create inconsistency elsewhere. Integration with CAT tools and, where appropriate, content management or labeling systems turns the assets from static files into active controls.
This is not theoretical process design. Multilingual terminology management standards such as ISO 30042 (TermBase eXchange) and the broader principles in ISO 704 and ISO 17100 already supply the technical and quality framework. Companies that treat the termbase and translation memory as living corporate assets rather than project by-products report fewer CAPAs related to labeling, faster time-to-submission in additional markets, and measurable reduction in review cycles.
The Broader Market Context
Demand for precise medical language services continues to expand as clinical trials, device registrations, and post-market surveillance become more global. Market analyses place the medical translation services segment in the low-to-mid billions of dollars and project continued growth driven by regulatory complexity, the rise of digital health interfaces, and the need for simultaneous multi-market launches. Consistency requirements under EU MDR/IVDR, FDA labeling rules, and national language mandates in markets from Canada to the GCC make centralized assets a practical necessity rather than a nice-to-have.
WHO’s MeDevIS platform and the push toward harmonized device nomenclature further underscore the value of standardized terminology. When regulators and procurement systems rely on shared codes and definitions, companies whose internal language assets mirror those standards reduce friction at every handoff.
Moving from Scattered Projects to an Enterprise Asset
The companies that move fastest are those that stop treating localization as a series of discrete translation jobs and start treating medical language as a strategic asset class. They inventory existing materials, reconcile conflicting terms before new work begins, embed the resulting termbase and translation memory into every subsequent project, and maintain clear ownership so that the assets remain accurate as products evolve and regulations change.
Artlangs Translation has spent more than two decades building precisely this kind of capability across regulated content. With coverage in over 230 languages and a network of more than 20,000 specialized linguists, the company has delivered localization programs for medical devices, pharmaceuticals, clinical materials, and related technical documentation. Its work extends beyond classic document translation into video localization, short-drama subtitle localization, game localization, multilingual audiobook dubbing, and large-scale data annotation and transcription—services that increasingly sit alongside traditional medical content as companies build comprehensive global communication systems. The same discipline that produces consistent IFUs and regulatory dossiers is applied to the broader set of multilingual assets medical brands now require.
A fragmented approach multiplies cost and risk with every new market. A systematic language asset strategy turns each project into an investment that reduces the cost and risk of the next one. For organizations serious about global medical markets, the question is no longer whether to build the library, but how quickly they can put it under disciplined control.
